Bisphosphonates, which are pyrophosphate analogues, are strong osteoclast inhibitors that are used in the treatment of osteoporosis and solid tumours with bony metastasis.The safe optimal dose and duration of treatment should be evaluated and the subset of patients at increased risk for osteonecrosis should be identified, as the necrosis seems to be irreversible and the treatment of these patients is very difficult